EUVIMEDEUVIMED entdecken
Crossref

Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study

Y. Wang, M. Qin, Z. Guochen, H. Guohui, D. Lixin, Z. Yafen, G. Xiangyang

European Journal of Cancer · 2026-03 · 237 · 116421

DOI: 10.1016/j.ejca.2026.116421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-03. Verfasst von Y. Wang und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wang, Y., Qin, M., Guochen, Z., Guohui, H., Lixin, D., Yafen, Z., & Xiangyang, G. (2026). Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study. European Journal of Cancer, 237, 116421. https://doi.org/10.1016/j.ejca.2026.116421

Vancouver

Wang Y, Qin M, Guochen Z, Guohui H, Lixin D, Yafen Z, et al. Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study. European Journal of Cancer. 2026;237:116421. doi:10.1016/j.ejca.2026.116421

BibTeX
@article{Wang2026,
  author = {Wang, Y. and Qin, M. and Guochen, Z. and Guohui, H. and Lixin, D. and Yafen, Z. and Xiangyang, G.},
  title = {Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {237},
  pages = {116421},
  doi = {10.1016/j.ejca.2026.116421}
}
Kostenlos starten →